Compare CENN & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENN | GDTC |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 15.5M |
| IPO Year | N/A | 2023 |
| Metric | CENN | GDTC |
|---|---|---|
| Price | $0.15 | $1.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 38.2K |
| Earning Date | 11-12-2025 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,529,541.00 | $573,193.00 |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.03 |
| 52 Week Low | $0.13 | $0.86 |
| 52 Week High | $1.23 | $3.68 |
| Indicator | CENN | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 30.59 |
| Support Level | $0.15 | $0.86 |
| Resistance Level | $0.16 | $1.39 |
| Average True Range (ATR) | 0.01 | 0.14 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 52.79 | 25.68 |
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles powered by either electricity or hydrogen energy sources. The company's commercial vehicles are designed to serve a variety of fleet and municipal organizations in support of city services, last-mile delivery, and other commercial applications. It has developed a series of commercial vehicle models, including Metro, Logistar, Logimax, Avantier, Teemak, and Antric One. In addition, the company has introduced an open-platform, programmable all-electric iChassis platform, designed for automated and autonomous driving. Geographically, the company generates maximum revenue from vehicle sales in the United States, and also has a presence in Europe, Asia, and other regions.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.